Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 23240 | 298 | 35.9 | 92% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 151 | 22214 | IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CANC VACCINE DEV | Address | 39 | 61% | 14% | 41 |
| 2 | INNOVAT CANC THER Y | Address | 22 | 24% | 27% | 81 |
| 3 | PERSONALIZED PEPTIDE VACCINE | Author keyword | 18 | 89% | 3% | 8 |
| 4 | IMMUNOL IMMUNOTHER Y | Address | 17 | 44% | 10% | 30 |
| 5 | SART3 | Author keyword | 8 | 75% | 2% | 6 |
| 6 | PEPTIDE VACCINE | Author keyword | 6 | 15% | 13% | 38 |
| 7 | ONCOANTIGEN | Author keyword | 4 | 75% | 1% | 3 |
| 8 | PERSONALIZED VACCINE | Author keyword | 4 | 75% | 1% | 3 |
| 9 | HLA A24 | Author keyword | 3 | 21% | 5% | 14 |
| 10 | SART3 ANTIGEN | Author keyword | 3 | 100% | 1% | 3 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | PERSONALIZED PEPTIDE VACCINE | 18 | 89% | 3% | 8 | Search PERSONALIZED+PEPTIDE+VACCINE | Search PERSONALIZED+PEPTIDE+VACCINE |
| 2 | SART3 | 8 | 75% | 2% | 6 | Search SART3 | Search SART3 |
| 3 | PEPTIDE VACCINE | 6 | 15% | 13% | 38 | Search PEPTIDE+VACCINE | Search PEPTIDE+VACCINE |
| 4 | ONCOANTIGEN | 4 | 75% | 1% | 3 | Search ONCOANTIGEN | Search ONCOANTIGEN |
| 5 | PERSONALIZED VACCINE | 4 | 75% | 1% | 3 | Search PERSONALIZED+VACCINE | Search PERSONALIZED+VACCINE |
| 6 | HLA A24 | 3 | 21% | 5% | 14 | Search HLA+A24 | Search HLA+A24 |
| 7 | SART3 ANTIGEN | 3 | 100% | 1% | 3 | Search SART3+ANTIGEN | Search SART3+ANTIGEN |
| 8 | KIF20A | 3 | 60% | 1% | 3 | Search KIF20A | Search KIF20A |
| 9 | TIP110 | 2 | 67% | 1% | 2 | Search TIP110 | Search TIP110 |
| 10 | HELPER T CELL EPITOPE | 1 | 38% | 1% | 3 | Search HELPER+T+CELL+EPITOPE | Search HELPER+T+CELL+EPITOPE |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | TUMOR SPECIFIC CTLS | 12 | 75% | 3% | 9 |
| 2 | SART3 DERIVED PEPTIDES | 12 | 86% | 2% | 6 |
| 3 | T LYMPHOCYTE PRECURSORS | 12 | 86% | 2% | 6 |
| 4 | IMMUNOLOGICAL EVALUATION | 9 | 24% | 11% | 33 |
| 5 | TAT INTERACTING PROTEIN | 7 | 67% | 2% | 6 |
| 6 | HLA A3 SUPERTYPE ALLELES | 6 | 80% | 1% | 4 |
| 7 | SUPERTYPE ALLELES | 6 | 80% | 1% | 4 |
| 8 | PULMONARY CARCINOGENESIS | 6 | 26% | 6% | 19 |
| 9 | ESOPHAGEAL CARCINOMAS | 5 | 40% | 3% | 10 |
| 10 | PROGNOSTIC BIOMARKER | 5 | 26% | 5% | 16 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Next-generation peptide vaccines for advanced cancer | 2013 | 22 | 54 | 44% |
| Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine | 2013 | 6 | 58 | 74% |
| Personalized peptide vaccines: A new therapeutic modality for cancer | 2006 | 24 | 23 | 65% |
| Recent Advances in Active Specific Cancer Vaccine Treatment for Colorectal Cancer | 2012 | 2 | 36 | 31% |
| Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses | 2015 | 0 | 53 | 38% |
| Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines | 2010 | 6 | 32 | 28% |
| Trial Watch Peptide vaccines in cancer therapy | 2013 | 17 | 147 | 10% |
| Advances in specific immunotherapy for prostate cancer | 2008 | 37 | 132 | 10% |
| Recent Advances in Cancer Vaccines: An Overview | 2009 | 27 | 56 | 11% |
| Vaccination therapy in prostate cancer | 2007 | 13 | 134 | 8% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CANC VACCINE DEV | 39 | 61% | 14% | 41 |
| 2 | INNOVAT CANC THER Y | 22 | 24% | 27% | 81 |
| 3 | IMMUNOL IMMUNOTHER Y | 17 | 44% | 10% | 30 |
| 4 | CANC VACCINE | 3 | 11% | 8.1% | 24 |
| 5 | KURUME UNIV INNOVAT CANC THER Y | 3 | 60% | 1.0% | 3 |
| 6 | 21ST CENTURY COE PROGRAM MED SCI | 2 | 22% | 2.3% | 7 |
| 7 | SURG BIOENGNMINATO KU | 1 | 38% | 1.0% | 3 |
| 8 | GENET CLIN ONCOL | 1 | 100% | 0.7% | 2 |
| 9 | COE PROGRAM MED SCI | 1 | 25% | 1.0% | 3 |
| 10 | 21 CENTURY COE PROGRAM MED SCI | 1 | 33% | 0.7% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000239023 | ANTIANGIOGENIC CANCER VACCINE//CELL PROTEOMIC FOOTPRINTING//HER1 VACCINE |
| 2 | 0.0000226476 | CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1 |
| 3 | 0.0000204510 | BELAGENPUMATUCEL L//SRL172//PA MSHA |
| 4 | 0.0000145637 | PBK TOPK//PDZ BINDING KINASE//PBK |
| 5 | 0.0000141353 | IMP3//IGF2BP3//L523S |
| 6 | 0.0000131691 | CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS |
| 7 | 0.0000130779 | 5T4//TUMOR IMMUNOL BIOL//5T4 ONCOFETAL ANTIGEN |
| 8 | 0.0000126609 | IEX 1//IMMEDIATE EARLY GENE X 1 IEX 1//IMMEDIATE EARLY RESPONSE GENE X 1 |
| 9 | 0.0000117581 | NORPEG//N COPINE//PSGR |
| 10 | 0.0000081789 | PROSTATE STEM CELL ANTIGEN//PROSTATE STEM CELL ANTIGEN PSCA//PSCA |